Fingerprint Dive into the research topics of 'Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?'. Together they form a unique fingerprint.
- Sort by
- Weight
- Alphabetically
Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?
Gennaro Riccio, Carmela Coppola, Giovanna Piscopo, Immacolata Capasso, Carlo Maurea, Emanuela Esposito, Claudia De Lorenzo, Nicola Maurea
Research output: Contribution to journal › Article › peer-review